BACKGROUND: In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and treating this rare mental health disorder. CASE PRESENTATION: Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a 35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4-methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic symptoms. He was initially treated with a combination of behav...
In this brief report we present the case of a 53 year old man with a very debilitating Generalized A...
Methylphenidate is one of the classic amphetamines which can cause or exacerbate psychotic symptoms ...
BACKGROUND: Zolpidem is a non-benzodiazepine medication which selectively affects GABA A receptors ...
BACKGROUND: In this report, we describe a case of a patient with substance-induced anxiety disorder ...
Abstract Background In this report, we describe a case of a patient with substance-induced anxiety d...
BACKGROUND: The high prevalence of comorbid illicit drug use in persons with chronic psychotic illne...
BACKGROUND: Over-the-counter medication overdose is a difficult diagnostic challenge for many physic...
BACKGROUND: The abuse of narcotic drugs and psychotropic substances such as amphetamines and ecstas...
Contains fulltext : 250444.pdf (Publisher’s version ) (Open Access)Background: Epi...
This document is an Accepted Manuscript reprinted from Journal of Addiction Medicine, Vol. 12 (3): 2...
Recent findings from the MRC-led South African Community Epidemiology Network on Drug Use (SACENDU) ...
Objective. This is a review of the current treatments used to alleviate the psychotic symptoms assoc...
3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress d...
This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issue...
Background: Methamphetamine use can produce symptoms almost indistinguishable from schizophrenia. Di...
In this brief report we present the case of a 53 year old man with a very debilitating Generalized A...
Methylphenidate is one of the classic amphetamines which can cause or exacerbate psychotic symptoms ...
BACKGROUND: Zolpidem is a non-benzodiazepine medication which selectively affects GABA A receptors ...
BACKGROUND: In this report, we describe a case of a patient with substance-induced anxiety disorder ...
Abstract Background In this report, we describe a case of a patient with substance-induced anxiety d...
BACKGROUND: The high prevalence of comorbid illicit drug use in persons with chronic psychotic illne...
BACKGROUND: Over-the-counter medication overdose is a difficult diagnostic challenge for many physic...
BACKGROUND: The abuse of narcotic drugs and psychotropic substances such as amphetamines and ecstas...
Contains fulltext : 250444.pdf (Publisher’s version ) (Open Access)Background: Epi...
This document is an Accepted Manuscript reprinted from Journal of Addiction Medicine, Vol. 12 (3): 2...
Recent findings from the MRC-led South African Community Epidemiology Network on Drug Use (SACENDU) ...
Objective. This is a review of the current treatments used to alleviate the psychotic symptoms assoc...
3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress d...
This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issue...
Background: Methamphetamine use can produce symptoms almost indistinguishable from schizophrenia. Di...
In this brief report we present the case of a 53 year old man with a very debilitating Generalized A...
Methylphenidate is one of the classic amphetamines which can cause or exacerbate psychotic symptoms ...
BACKGROUND: Zolpidem is a non-benzodiazepine medication which selectively affects GABA A receptors ...